Drug Trial Radar · NCT07446309
Safety and Efficacy of HRS-9190 Compared to Cisatracurium for Continuous Intravenous Infusion in Adults
Last checked: Nov 20, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
67
Actual
Start
Apr 10, 2026
Primary completion
Jul 14, 2026
Study completion Jul 29, 2026
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will enroll adult patients scheduled for elective surgery requiring general anesthesia. Participants will be randomly assigned to receive either HRS-9190 for Injection or Cisatracurium. The primary objective is to measure the duration from cessation of the study drug infusion until the recovery of neuromuscular function to a specific level (TOFr ≥ 90%). Secondary objectives include onset time, duration of action, total time of adequate muscle relaxation during surgery, and neuromuscular recovery pattern.. Safety assessments will include monitoring of adverse events, vital signs, laboratory parameters, and other safety indicators throughout the study period. The hypothesis of this study is that HRS-9190 for Injection could provide effective neuromuscular relaxation, with a satisfied safety profile in the target patient population.
Conditions
- Neuromuscular Blockade
Interventions
HRS-9190; under Inhalational AnesthesiaDrug
HRS-9190; under Inhalational Anesthesia
HRS-9190; under Intravenous AnesthesiaDrug
HRS-9190; under Intravenous Anesthesia
Cisatracurium (under Inhalational Anesthesia).Drug
Cisatracurium (under Inhalational Anesthesia).
Cisatracurium (under Intravenous Anesthesia)Drug
Cisatracurium (under Intravenous Anesthesia)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time from Cessation of Infusion to Recovery of TOFr to 0.9Time frame: From the end of continuous infusion of the study drug until the time point when TOFr ≥ 90% is first achieved, assessed intraoperatively and in the immediate postoperative period, up to 2 hours
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
ZhongShan Hospital Fudan University
Shanghai, Shanghai Municipality, China
Shanxi Provincial People'S Hospital
Taiyuan, Shanxi, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.